Aurobindo Pharma eyes $5-B revenue in 5 years

Aurobindo Pharma has undergone a significant reorganisation, restructuring its operations into three subsidiaries. Eugia Pharma Specialities is dedicated to injectables and specialty oral solid dosages; Curateq Biologics focusing on vaccines, biosimilars, and peptides; Apitoria Pharma, an API division.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5FnXvRm
via IFTTT